鸢尾素/FNDC5对儿童青少年身体代谢影响研究进展

张径遂; 杨坡; 阿力木·热合曼; 何恩鹏

doi:10.16835/j.cnki.1000-9817.2021.08.034

鸢尾素/FNDC5对儿童青少年身体代谢影响研究进展

doi: 10.16835/j.cnki.1000-9817.2021.08.034

新疆师范大学体育学院运动人体科学重点实验室，乌鲁木齐 830054

基金项目:

新疆维吾尔自治区高校科研计划项目 XJEDU2020Y032

新疆维吾尔自治区研究生科研创新项目 XJ2020G225

详细信息

作者简介:
张径遂(1994-)，男，新疆塔城人，在读硕士，主要研究方向为运动健康促进

通讯作者:
何恩鹏，E-mail：heenpeng@sina.com

中图分类号: R179 R725.8
计量
- 文章访问数: 660
- HTML全文浏览量: 312
- PDF下载量: 43
- 被引次数: 0
出版历程
- 收稿日期: 2020-11-28
- 修回日期: 2021-01-20
- 网络出版日期: 2021-08-20
- 刊出日期: 2021-08-25

Research update on the effect of irisin/FNDC5 on metabolism of children and adolescents

Key Laboratory of Human Body Science, College of Physical Education, Xinjiang Normal University, Urumqi (830054), China

摘要

摘要: 儿童青少年身体代谢水平在儿童青少年的健康成长发育方面具有重要意义。鸢尾素(Irisin)作为一种肌肉因子，于2012年被首次发现并命名，早期研究结果显示其可以参与身体代谢，抑制肥胖的发生，随后又发现Irisin具有改善2型糖尿病、代谢综合征、骨质疏松症等疾病症状的作用。同时，Irisin对儿童青少年糖脂代谢和骨代谢具有促进作用，但其作用机制还存在争议。本研究综述Irisin在国内外儿童青少年身体代谢方面的相关报道，为研究儿童青少年身体代谢提供理论参考依据。
- 能量代谢 /
- 鸢尾素 /
- 儿童 /
- 青少年
Abstract: The metabolic level of children and adolescents is of great significance in the healthy growth and development of children and adolescents. Irisin, as a myokine, was first discovered and named in 2012. Early studies showed that irisin can participate in body metabolism and inhibit the occurrence of obesity. Later studies found that irisin can improve the symptoms of type 2 diabetes mellitus, metabolic syndrome, osteoporosis and other diseases. At the same time, irisin can promote glucose, lipid metabolism and bone metabolism in children and adolescents, and its mechanism is still controversial. In this review, research update regarding the effect of irisin/FNDC5 on metabolism (lipid metabolism, glucose metabolism, bone metabolism) in children and adolescents were summarized in order to provide theoretical reference for researchers in the field of the metabolism of children and adolescents.
- Energy metabolism /
- Irisin /
- Child /
- Adolescent

HTML全文

参考文献(67)

[1]	冯俊鹏, 严翊. 国内外儿童、青少年体力活动现状分析: 基于2018年《全球儿童、青少年体力活动报告》[J]. 中国运动医学杂志, 2019, 38(12): 1094-1100. doi: 10.3969/j.issn.1000-6710.2019.12.013 FENG J P, YAN Y. Analysis on the current situation of physical activity of children and adolescents at home and abroad: based on the 2018 global report on physical activity of children and adolescents[J]. Chin J Sports Med, 2019, 38(12): 1094-1100. doi: 10.3969/j.issn.1000-6710.2019.12.013
[2]	MCLOUGHLIN G M, BAI Y, WELK G J. Longitudinal associations between physical fitness and academic achievement in youth[J]. Med Sci Sports Exerc, 2020, 52(3): 616-622. doi: 10.1249/MSS.0000000000002159
[3]	BOSTRM P, WU J, JEDRYCHOWSKI M P, et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis[J]. Nature, 2012, 481(7382): 463-468. doi: 10.1038/nature10777
[4]	AYDIN S, KULOGLU T, AYDIN S, et al. Cardiac, skeletal muscle and serum irisin responses to with or without water exercise in young and old male rats: cardiac muscle produces more irisin than skeletal muscle[J]. Peptides, 2014, 52(2): 68-73. http://smartsearch.nstl.gov.cn/paper_detail.html?id=884fef0063f56b040545a0e3f525c1eb
[5]	AYDIN S, KULOGLU T, YILMAZ M, et al. Alterations of Irisin concentrations in saliva and serum of obese and normal-weight subjects, before and after 45 min of a Turkish bath or running[J]. Peptides, 2013, 50(complete): 13-18. http://europepmc.org/abstract/med/24096106
[6]	HECKSTEDEN A, WEGMANN M, STEFFEN A, et al. Irisin and exercise training in humans-results from a randomized controlled training trial[J]. BMC Med, 2013, 11(1): 235. doi: 10.1186/1741-7015-11-235
[7]	GOUVEIA M C, VELLA J P, CAFEO F K, et al. Association between irisin and major chronic disease: a review[J]. Eur Rev Med Pharmacol Sci, 2016, 20(19): 4072-4077. http://www.ncbi.nlm.nih.gov/pubmed/27775791
[8]	POLYZOS S A, ANASTASILAKIS A D, EFSTATHIADOU Z A, et al. Irisin in metabolic diseases[J]. Endocrine, 2018, 59(2): 260-274. doi: 10.1007/s12020-017-1476-1
[9]	PERAKAKIS N, TRIANTAFYLLOU G A, FERNÁNDEZ-REAL J M, et al. Physiology and role of Irisin in glucose homeostasis[J]. Nat Rev Endocrinol, 2017, 13(6): 324-337. doi: 10.1038/nrendo.2016.221
[10]	REILLY J J, KELLY J. Long-term impact of overweight and obesity in childhood and adolescence on morbidity and premature mortality in adulthood: systematic review[J]. Int J Obes, 2011, 35(Suppl 4): 891-898. http://www.bmj.com/lookup/external-ref?access_num=20975725&link_type=MED&atom=%2Fbmj%2F346%2Fbmj.f3092.atom
[11]	JANG H B, KIM H J, KANG J H, et al. Association of circulating irisin levels with metabolic and metabolite profiles of Korean adolescents[J]. Metabolism, 2017, 73(8): 100-108. http://www.ncbi.nlm.nih.gov/pubmed/28732566
[12]	HEE P, ZAICHENKO L, BRINKOETTER M, et al. Circulating Irisin in relation to insulin resistance and the metabolic syndrome[J]. J Clin Endocrinol Metab, 2013, 98(12): 4899-4907. doi: 10.1210/jc.2013-2373
[13]	PYRAK B, DEMKOW U, KUCHARSKA A M. Brown adipose tissue and browning agents: Irisin and FGF21 in the development of obesity in children and adolescents[M]. Cham: Springer, 2015: 25-34.
[14]	LETICIA E M, CHRISTIAN S P, ALEJANDRO T Q, et al. Association of Irisin plasma levels with anthropometric parameters in children with underweight, normal weight, overweight, and obesity[J]. Bio Med Res Int, 2017, 2017(5-3): 2628968. http://europepmc.org/articles/PMC5434279/
[15]	PALACIOS-GONZÁLEZ B, VADILLO-ORTEGA F, POLO-OTEYZA E, et al. Irisin levels before and after physical activity among school-age children with different BMI: a direct relation with leptin[J]. Obesity, 2015, 23(4): 729-732. doi: 10.1002/oby.21029
[16]	GONZALEZ-GIL A M, PESCHARD-FRANCO M, CASTILLO E C, et al. Myokine-adipokine cross-talk: potential mechanisms for the association between plasma irisin and adipokines and cardiometabolic risk factors in Mexican children with obesity and the metabolic syndrome[J]. Diabetol Metab Syndr, 2019, 11(1): 63. doi: 10.1186/s13098-019-0458-2
[17]	SHIM Y S, KANG M J, YANG S, et al. Irisin is a biomarker for metabolic syndrome in prepubertal children[J]. Endocr J, 2018, 65(1): 23-31. doi: 10.1507/endocrj.EJ17-0260
[18]	ELIZONDO-MONTEMAYOR L, GONZALEZ-GIL A M, TAMEZ-RIVERA O, et al. Association between Irisin, hs-CRP, and metabolic status in children and adolescents with type 2 diabetes mellitus[J]. Mediators Inflamm, 2019, 2019: 6737318.
[19]	YIN C, HU W, WANG M, et al. Irisin as a mediator between obesity and vascular inflammation in Chinese children and adolescents[J]. Nutr Metab Cardiovasc Dis, 2020, 30(2): 320-329. doi: 10.1016/j.numecd.2019.09.025
[20]	BLVHER S, PANAGIOTOU G, PETROFF D, et al. Effects of a 1-year exercise and lifestyle intervention on Irisin, adipokines, and inflammatory markers in obese children[J]. Obesity, 2014, 22(7): 1701-1708. doi: 10.1002/oby.20739
[21]	REINEHR T, ELFERS C, LASS N, et al. Irisin and its relation to insulin resistance and puberty in obese children: a longitudinal analysis[J]. J Clin Endocrinol Metab, 2015, 100(5): 2123-2130. doi: 10.1210/jc.2015-1208
[22]	KARAMPATSOU S I, GENITSARIDI S M, PAPAGEORGIOU I, et al. The role of fibroblast growth factor 21 and Irisin in the pathogenesis of obesity in childhood and adolescence[C]//Hormone Research in Paediatrics. Allschwilerstrasse 10, CH-4009 Basel, Switzerland: Karger, 2018: 323.
[23]	VⅡTASALO A, GREN J, VENLINEN T, et al. Association of plasma fatty acid composition with plasma Irisin levels in normal weight and overweight/obese children[J]. Pediatr Obes, 2016, 11(4): 299-305. doi: 10.1111/ijpo.12062
[24]	SEPP S, TENHOLA S, VOUTILAINEN R. Fibroblast Growth Factor 21, Adiponectin, and Irisin as markers of unfavorable metabolic features in 12-year-old children[J]. J Endocr Soc, 2019, 3(4): 825-837. doi: 10.1210/js.2018-00399
[25]	NIGRO E, SCUDIERO O, MONACO M L, et al. Adiponectin profile and Irisin expression in Italian obese children: association with insulin-resistance[J]. Cytokine, 2017, 94(6): 8-13. http://www.sciencedirect.com/science/article/pii/S1043466616306044
[26]	AL-DAGHRI N M, ALKHARFY K M, RAHMAN S, et al. Irisin as a predictor of glucose metabolism in children: sexually dimorphic effects[J]. Eur J Clin Invest, 2014, 44(2): 119-124. doi: 10.1111/eci.12196
[27]	WU J, BOSTRM P, SPARKS L M, et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human[J]. Cell, 2012, 150(2): 366-376. doi: 10.1016/j.cell.2012.05.016
[28]	IRVING B A, STILL C D, ARGYROPOULOS G. Does IRISIN have a BRITE future as a therapeutic agent in humans?[J]. Curr Obes Rep, 2014, 3(2): 235-241. doi: 10.1007/s13679-014-0091-1
[29]	NIRANJAN S B, BELWALKAR S V, TAMBE S, et al. Recombinant irisin induces weight loss in high fat DIO mice through increase in energy consumption and thermogenesis[J]. Biochem Biophys Res Commun, 2019, 519(2): 422-429. doi: 10.1016/j.bbrc.2019.08.112
[30]	TSAI Y C, WANG C W, WEN B Y, et al. Involvement of the p62/Nrf2/HO-1 pathway in the browning effect of irisin in 3T3-L1 adipocytes[J]. Mol Cell Endocrinol, 2020, 514(8): 110915.
[31]	LI H, ZHANG Y, WANG F, et al. Original Article Effects of irisin on the differentiation and browning of human visceral white adipocytes[J]. Am J Transl Res, 2019, 11(12): 7410-7421. http://www.ncbi.nlm.nih.gov/pubmed/31934288
[32]	HUH J Y, DINCER F, MESFUM E, et al. Irisin stimulates muscle growth-related genes and regulates adipocyte differentiation and metabolism in humans[J]. Int J Obes, 2014, 38(12): 1538-1544. doi: 10.1038/ijo.2014.42
[33]	SESTI G, ANDREOZZI F, FIORENTINO T V, et al. High circulating Irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects[J]. Acta Diabetolog, 2014, 51(5): 705-713. doi: 10.1007/s00592-014-0576-0
[34]	CHEN N, LI Q, LIU J, et al. Irisin, an exercise-induced myokine as a metabolic regulator: an updated narrative review[J]. Diabet Metab Res Rev, 2016, 32(1): 51-59. doi: 10.1002/dmrr.2660
[35]	MORENO N, FRANCISCO O, MARTA S, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance[J]. J Clin Endocrinol Metab, 2013, 98(4): E769-E778. doi: 10.1210/jc.2012-2749
[36]	LIU T Y, SHI C X, GAO R, et al. Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes[J]. Clin Sci, 2015, 129(10): 839-850. doi: 10.1042/CS20150009
[37]	HUANG L, YAN S, LUO L, et al. Irisin regulates the expression of BDNF and glycometabolism in diabetic rats[J]. Mol Med Rep, 2019, 19(2): 1074-1082. http://www.ncbi.nlm.nih.gov/pubmed/30569121
[38]	HUH J Y, PANAGIOTOU G, MOUGIOS V, et al. FNDC5 and Irisin in humans: I. Predictors of circulating concentrations in serum and plasma and Ⅱ. mRNA expression and circulating concentrations in response to weight loss and exercise[J]. Metabolism, 2012, 61(12): 1725-1738. doi: 10.1016/j.metabol.2012.09.002
[39]	PANG Y, ZHU H, XU J, et al. β-arrestin-2 is involved in Irisin induced glucose metabolism in type 2 diabetes via p38 MAPK signaling[J]. Exp Cell Res, 2017, 360(2): 199-204. doi: 10.1016/j.yexcr.2017.09.006
[40]	TANG H, YU R, LIU S, et al. Irisin inhibits hepatic cholesterol synthesis via AMPK-SREBP2 signaling[J]. EbioMedicine, 2016, 6: 139-148. doi: 10.1016/j.ebiom.2016.02.041
[41]	LIU T Y, SHI C X, GAO R, et al. Irisin inhibits hepatic gluconeogenesis and increases glycogen synthesis via the PI3K/Akt pathway in type 2 diabetic mice and hepatocytes[J]. Clin Sci, 2015, 129(10): 839-850. doi: 10.1042/CS20150009
[42]	ZHOU Q, CHEN K, LIU P, et al. Dihydromyricetin stimulates irisin secretion partially via the PGC-1α pathway[J]. Mol Cell Endocrinol, 2015, 412(9): 349-357. http://cpfd.cnki.com.cn/Article/CPFDTOTAL-EGYN201505001366.htm
[43]	ZHANG Y, LI R, MENG Y, et al. Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling[J]. Diabetes, 2014, 63(2): 514-525. doi: 10.2337/db13-1106
[44]	LOOMBA-ALBRECHT L A, STYNE D M. Effect of puberty on body composition[J]. Curr Opin Endocrinol Diabet Obes, 2009, 16(1): 10-15. doi: 10.1097/MED.0b013e328320d54c
[45]	SOPHER A B, FENNOY I, OBERFIELD S E. An update on childhood bone health: mineral accrual, assessment and treatment[J]. Curr Opin Endocrinol Diabet Obes, 2015, 22(1): 35-40. doi: 10.1097/MED.0000000000000124
[46]	SOININEN S, SIDOROFF V, LINDI V, et al. Body fat mass, lean body mass and associated biomarkers as determinants of bone mineral density in children 6-8 years of age-The Physical Activity and Nutrition in Children (PANIC) study[J]. Bone, 2018, 108(3): 106-114. http://www.sciencedirect.com/science/article/pii/S8756328218300036
[47]	COLAIANNI G, FAIENZA M F, SANESI L, et al. Irisin serum levels are positively correlated with bone mineral status in a population of healthy children[J]. Pediatr Res, 2019, 85(4): 484-488. doi: 10.1038/s41390-019-0278-y
[48]	FAIENZA M F, BRUNETTI G, SANESI L, et al. High Irisin levels are associated with better glycemic control and bone health in children with type 1 diabetes[J]. Diabet Res Clin Pract, 2018, 141(7): 10-17. http://d.wanfangdata.com.cn/periodical/e8f97e336858623b7bafc3c3185285a1
[49]	GRANO M, COLAIANNI G, CUSCITO C, et al. Irisin for care and prevention of osteoporosis: U.S. 15/098, 418[P]. 2017-02-02.
[50]	ZHOU K, QIAO X, CAI Y, et al. Lower circulating Irisin in middle-aged and older adults with osteoporosis: a systematic review and meta-analysis[J]. Menopause, 2019, 26(11): 1302-1310. doi: 10.1097/GME.0000000000001388
[51]	WU L F, ZHU D C, TANG C H, et al. Association of plasma Irisin with bone mineral density in a large chinese population using an extreme sampling design[J]. Calcif Tissue Int, 2018, 103(3): 246-251. doi: 10.1007/s00223-018-0415-3
[52]	BONFANTE I L P, CHACON-MIKAHIL M P T, BRUNELLI D T, et al. Obese with higher FNDC5/Irisin levels have a better metabolic profile, lower lipopolysaccharide levels and type 2 diabetes risk[J]. Arch Endocrinol Metab, 2017, 61(6): 524-533. doi: 10.1590/2359-3997000000305
[53]	COLAIANNI G, CUSCITO C, MONGELLI T, et al. Irisin enhances osteoblast differentiation in vitro[J]. Int J Endocrinol, 2014(2014): 902186. http://www.ncbi.nlm.nih.gov/pubmed/24723951
[54]	田梦婷, 刘晶, 曾雪敏, 等. 鸢尾素对大鼠骨髓间充质干细胞Sost基因表达及成骨分化的影响[J]. 中华口腔医学研究杂志(电子版), 2019, 13(3): 144-150. doi: 10.3877/cma.j.issn.1674-1366.2019.03.003 TIAN M T, LIU J, ZENG X M, et al. Effect of Irisin on osteogenic differentiation and Sost of rat bone marrow mesenchymal stem cells[J]. Chin J Stomatol Res (Elect Ed), 2019, 13(3): 144-150. doi: 10.3877/cma.j.issn.1674-1366.2019.03.003
[55]	MA Y, QIAO X, ZENG R, et al. Irisin promotes proliferation but inhibits differentiation in osteoclast precursor cells[J]. Faseb J, 2018, 32(11): 5813-5823. doi: 10.1096/fj.201700983RR
[56]	COLAIANNI G, NOTARNICOLA A, SANESI L, et al. Irisin levels correlate with bone mineral density in soccer players[J]. J Biol Regul Homeostat Agents, 2017, 31(Suppl 1): 21-28. http://www.ncbi.nlm.nih.gov/pubmed/29181953
[57]	METZGER C E, NARAYANAN S A, ELIZONDO J P, et al. DSS-induced colitis produces inflammation-induced bone loss while Irisin treatment mitigates the inflammatory state in both gut and bone[J]. Sci Rep, 2019, 9(1): 423-439. doi: 10.1038/s41598-018-36714-4
[58]	QIAO X, NIE Y, MA Y, et al. Irisin promotes osteoblast proliferation and differentiation via activating the MAP kinase signaling pathways[J]. Sci Rep, 2016, 6(1): 817-831. http://europepmc.org/articles/PMC4704023/
[59]	STORLINO G, COLAIANNI G, SANESI L, et al. Irisin prevents disuse-induced osteocyte apoptosis[J]. J Bone Miner Res, 2020, 35(4): 766-775. doi: 10.1002/jbmr.3944
[60]	WANG F S, KUO C W, KO J Y, et al. Irisin mitigates oxidative stress, chondrocyte dysfunction and osteoarthritis development through regulating mitochondrial integrity and autophagy[J]. Antioxidants, 2020, 9(9): 810. doi: 10.3390/antiox9090810
[61]	CHEN X, SUN K, ZHAO S, et al. Irisin promotes osteogenic differentiation of bone marrow mesenchymal stem cells by activating autophagy via the Wnt//β-catenin signal pathway[J]. Cytokine, 2020, 136(12): 155292. http://www.sciencedirect.com/science/article/pii/S1043466620303082
[62]	HE Z, LI H, HAN X, et al. Irisin inhibits osteocyte apoptosis by activating the Erk signaling pathway in vitro and attenuates ALCT-induced osteoarthritis in mice[J]. Bone, 2020, 141(12): 115573.
[63]	COLAIANNI G, SANESI L, STORLINO G, et al. Irisin and bone: From preclinical studies to the evaluation of its circulating levels in different populations of human subjects[J]. Cells, 2019, 8(5): 451. doi: 10.3390/cells8050451
[64]	COLAIANNI G, CUSCITO C, MONGELLI T, et al. The myokine irisin increases cortical bone mass[J]. Proc Natl Acad Sci, 2015, 112(39): 12157-12162. doi: 10.1073/pnas.1516622112
[65]	ZHANG J, VALVERDE P, ZHU X, et al. Exercise-induced Irisin in bone and systemic Irisin administration reveal new regulatory mechanisms of bone metabolism[J]. Bone Res, 2017, 5(1): 49-62. http://d.wanfangdata.com.cn/Periodical_gyj-e201701005.aspx
[66]	KANG Y S, KIM J C, KIM J S, et al. Effects of swimming exercise on serum irisin and bone FNDC5 in rat models of high-fat diet-induced osteoporosis[J]. J Sport Sci Med, 2019, 18(4): 596-603. http://www.ncbi.nlm.nih.gov/pubmed/31827343
[67]	VIBHA S, LAWSON E A, ACKERMAN K E, et al. Irisin levels are lower in young amenorrheic athletes compared with eumenorrheic athletes and non-athletes and are associated with bone density and strength estimates[J]. PLoS One, 2014, 9(6): e100218. doi: 10.1371/journal.pone.0100218